RECEIVED BY TIC FEB 12 1973

RADIOISOTOPE PROGRAM (8000) PROGRESS REPORT FOR JANUARY 1973

A. F. Rupp

OAK RIDGE NATIONAL LABORATORY

OPERATED BY UNION CARBIDE CORPORATION • FOR THE U.S. ATOMIC ENERGY COMMISSION

MASTER

DISTRIBUTION OF THIS DOCUMENT IS UNLIMITED

DISCLAIMER

This report was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency Thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof.

DISCLAIMER

Portions of this document may be illegible in electronic image products. Images are produced from the best available original document.

This report was prepared as an account of work sponsored by the United States Government. Neither the United States nor the United States Atomic Energy Commission, nor any of their employees, nor any of their contractors, subcontractors, or their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness or usefulness of any information, apparatus, product or process disclosed, or represents that its use would not infringe privately owned rights.

Contract No. W-7405-eng-26

ISOTOPE DEVELOPMENT CENTER

RADIOISOTOPE PROGRAM (8000) PROGRESS REPORT
FOR JANUARY 1973

A. F. Rupp

Work Sponsored by
AEC Division of Applied Technology

FEBRUARY 1973

NOTICE This document contains information of a preliminary nature and was prepared primarily for internal use at the Oak Ridge National Laboratory. It is subject to revision or correction and therefore does not represent a final report.

OAK RIDGE NATIONAL LABORATORY
Oak Ridge, Tennessee 37830
operated by
UNION CARBIDE CORPORATION
for the
U.S. ATOMIC ENERGY COMMISSION

MASTER

DISTRIBUTION OF THIS DOCUMENT IS UNLIMITED

THIS PAGE
WAS INTENTIONALLY
LEFT BLANK

CONTENTS

	<u>Page</u>
RADIOISOTOPE PRODUCTION AND MATERIALS DEVELOPMENT	1
REACTOR-PRODUCED ISOTOPES	1
Phosphorus-33	1
Potassium-43	2
Platinum-195m	3
Reactor Products Pilot Production	3
ACCELERATOR-PRODUCED ISOTOPES	3
Bismuth-206	3
Cyclotron Products Pilot Production	5
FISSION PRODUCTS	5
Krypton-85 Enrichment	5
Cesium-137 Pilot Production	6
Strontium-90 Pilot Production	7
Promethium-147 Shipments and Current Orders	8
SOURCE DEVELOPMENT	8
Americium-241	8
Gadolinium-153	9
Prototype Source Testing	9
Radioisotope Characterization, Quality Control, and Standards	9
RADIOISOTOPE SALES	11
ADMINISTRATION	13
PUBLICATIONS	13
REPORTS	13

RADIOISOTOPE PROGRAM (8000) PROGRESS REPORT
FOR JANUARY 1973

A. F. Rupp

RADIOISOTOPE PRODUCTION AND MATERIALS DEVELOPMENT

REACTOR-PRODUCED ISOTOPES — 08-01-01

Phosphorus-33 (T. A. Butler)

The purpose of this project is to develop methods of preparing hundred-millicurie quantities of carrier-free phosphorus-33 containing $\leq 5\%$ phosphorus-32. The two methods for producing phosphorus-33 being evaluated are based on the irradiation of highly enriched targets of sulfur-33 (>92 at. %) or chlorine-36 (approximately 63 at. %) in a fast neutron flux. Phosphorus-33 (25.2 days; 0.248-MeV $\beta_{\max}$) has both a longer half-life and a lower energy beta than phosphorus-32 (14.3 days; 1.709-MeV $\beta_{\max}$), which makes it advantageous for autoradiography, longer ecological and agricultural experiments than with phosphorus-32, synthesis of tagged complex organophosphorus compounds, and double labeling experiments.

A 1.06-g $K^{36}Cl$ target which had been irradiated for two cycles in HFIR was processed. It was dissolved in water and converted by ion exchange to $H^{36}Cl$; freshly precipitated $Fe(OH)_3$ was dissolved in the acid solution and then cesium-free KOH was added to adjust the pH to 9. As experienced in the preceding target processing, a low-product yield was obtained, in this case only 80 mCi or $\sim 10\%$ of what was expected. The phosphorus-32 content was 6% at time of processing, and it was combined with product remaining from a previous batch to provide an acceptable product to fill a 100-mCi order.

A beta-absorption study of the dissolved target solution revealed that about 900 mCi phosphorus-33 remained in solution. The changed processing procedure uses a KOH precipitation of $Fe(OH)_3$ instead of the NH_4OH previously used. The erratic yields have occurred since this change. A tracer level experiment with phosphorus-32 was performed to test whether the ability of $Fe(OH)_3$ to carry PO_4^{3-} was sensitive to this. In the single experiment performed, however, both the KOH and NH_4OH precipitations carried $\sim 95\%$ of the PO_4^{3-} . There was a slight indication that the KOH procedure was less efficient, but more experiments are required. The target solution will be reprocessed to recover the additional phosphorus-33.

Potassium-43 (T. A. Butler)

The objectives of this project are to prepare potassium-43 by the $^{43}\text{Ca}(n,p)^{43}\text{K}$ reaction, using isotopically enriched ^{43}CaO targets and to establish cooperative programs with medical institutions to evaluate it. Potassium-43 is potentially useful for metabolic and clinical studies of blood flow, rejection of transplanted organs, and kidney function. The half-life of potassium-43 is 22.5 hr; gamma-rays are 0.373 and 0.617 MeV.

Two batches of potassium-43 were processed this month, and four shipments totaling 15.5 mCi were made.

The Society of Nuclear Medicine sponsored a symposium on cardiac imaging in nuclear medicine in Chicago. A clinician reviewed the clinical needs for reproducible techniques applicable to critically ill patients for quantifying infarcts and defining salvageable ischemic areas amenable to surgery. He illustrated the significant risk involved in the invasive techniques, which are in current practice, and their inadequacy when applied to hearts with gross physical abnormalities. An interesting report from a Harvard group was the fact that acute infarct areas could be selectively labeled by technetium-99m-labeled tetracycline provided there was still some vascular blood supply to the infarcted area. Cesium-129 appears to have little or no advantage over potassium-43 and suffers a disadvantage in its slower uptake and clearance rates. While the 1.25-min rubidium-82, which could be readily available from a 25-day strontium-82 generator, most nearly resembles potassium physiologically and gave promising results with animals, it has been somewhat disappointing in the few human studies.

The Johns Hopkins group presented studies defining ischemic areas by scanning with potassium-43 given at rest and then given subsequent to strenuous exercise. In this application potassium-43 probably has a distinct advantage because potassium is physiological, whereas other agents may be just as adequate for studies of infarction.

The general conclusions drawn are that much progress has been made, but the wide variation in quality of images underscores how much needs to be done, especially in this area. It appears that potassium-43 has a significant place in cardiac imaging, but it must be more available and at lower cost.

In pursuit of both objectives of quantity and economy we have begun assembling the calcium oxide target to test the production yield via the $^{43}\text{Ca}(\gamma,p)^{43}\text{K}$ photonuclear reaction.¹ The experiment itself requires a large (>600 lb. CaO) target from which selective samples will be taken.

¹A. F. Rupp, *Radioisotope Program (8000) Progress Report for November 1972*, ORNL-TM-4067, Oak Ridge National Laboratory.

Production of potassium-43 by this mechanism would involve costly processing of large quantities of target materials, but the deliverable product would be in the decicurie range with net reduction in unit costs. Expanded production at reduced cost is a prerequisite to any widespread clinical role for potassium-43.

Platinum-195m (T. A. Butler)

The objectives of this work are to develop methods for preparing platinum isotopes suitable for whole-body scanning in biological and medical experiments, to characterize the products, and to establish cooperative programs with medical research groups interested in evaluating their usefulness.

Recent medical research has shown that some platinum compounds act as chemical therapeutic agents towards certain kinds of tumors. Platinum radioisotopes are needed for investigation of the therapeutic mechanism involved. Platinum-195m (4.0 d) has gamma emissions of 99 keV (11%) and 129 keV (2.8%) that make it suitable for whole-body scanning.

Two shipments of platinum-195m, totaling ~60 mCi, were made to the University of Southern California under our cooperative program.

Reactor Products Pilot Production (R. W. Schaich) (Production and Inventory Accounts)

<u>Processed Units</u>	
<u>Radioisotope</u>	<u>Amount (mCi)</u>
Copper-67	58
Calcium-47	4.3
Zinc-69m	163

ACCELERATOR-PRODUCED ISOTOPES — 08-01-02

Bismuth-206 (T. A. Butler)

The objectives of this program are to evaluate the pertinent production parameters and to provide bismuth-206 (8.24 d) for evaluation as a diagnostic radionuclide in medicine. Bismuth-206 has been used to delineate brain tumors in patients with known brain tumors which are poorly visualized by more common radionuclides. Even though very favorable tumor-to-background activity ratio has been obtained by earlier workers, the lack of an appropriate scanning

system suitable for the high-energy emissions of this nuclide has retarded the evaluation of the isotope. Cooperative programs have been established with Vanderbilt Medical School and the Medical Division of ORAU for the evaluation of bismuth-206 as a diagnostic radionuclide using high-energy photon scanning systems.

Development of an electrodeposited lead-on-copper cyclotron target suitable for use with highly enriched lead-207 target material has been resumed.² Use of an approximately 1.5 M fluoboric acid (HBF_4) electrolyte, containing 2 to 3 g lead [added as PbCO_3 or $2 \text{ PbCO}_3 \cdot \text{Pb}(\text{OH})_2$], a small amount of bone glue additive, and an inert platinum screen anode have yielded targets with smooth, tightly adherent lead plates ranging in thickness from 3.3 to 7.9 mils average. Test irradiation of these targets, prepared from natural isotopic abundance lead, has begun and will be continued to determine the effect of target thickness on yield and the effect of proton beam power levels on target integrity before starting an extensive production effort with highly enriched lead-207. The low-purity bismuth-206 produced during the testing of the natural lead targets ($\sim 35\%$ bismuth-205, 15.3 d, at end of bombardment, EOB) will be distributed to collaborative investigators for preliminary animal distribution studies, which will not require the lower dose, higher purity bismuth-206 (estimated to be $\leq 5\%$ bismuth-205 EOB) to be prepared from the enriched lead-207 for human studies. In order to confirm the estimated purity of a bismuth-206 product prepared via the $^{207}\text{Pb}(p,2n)^{206}\text{Bi}$ reaction using enriched lead-207, a 2.7-mil-thick lead-207 electrodeposited target (92.4 at. % isotopically enriched lead-207, 2.16 at. % lead-206) was irradiated in the ORNL 86-Inch Cyclotron at low beam current ($\sim 140 \mu\text{A}$) with 22-MeV protons, the carrier-free bismuth was recovered and purified, and the product radionuclidic purity was characterized. The EOB composition of the bismuth was found to be $>98\%$ bismuth-206 and $\sim 1.5\%$ bismuth-205 (15.3 d), well within the earlier estimates.

The irradiated lead is electrostripped into $\sim 1.5 \text{ M HNO}_3$, the aqueous phase is then diluted to $\sim 0.3 \text{ M HNO}_3$, and then the Bi^{3+} is extracted from the aqueous phase using a 0.3 M solution of di(2-ethylhexyl)-phosphoric acid (HDEHP) in n-heptane as developed by Neirinckx.³ Preliminary experiments using this chemical process indicate that it is more efficient than processes used earlier.² The distribution coefficients for $\text{Cu}(\text{II})$, $\text{Pb}(\text{II})$, and $\text{Zn}(\text{II})$ [zinc-62 (9.15 h) and zinc-65 (243 d) are formed by (p,xn) reaction on the copper target substrate] are all ≤ 0.1 under these extraction conditions; whereas, the distribution coefficient for $\text{Bi}(\text{III})$ is approximately 40. Total process chemical yields $>90\%$ would seem possible using this basic separation and purification procedure. Additional work will be done on process testing and optimization and on product characterization in the future, with the products being distributed to collaborative investigators for evaluation.

²A. F. Rupp, *Radioisotope Program (8000) Progress Report for April 1971*, ORNL-TM-3414, Oak Ridge National Laboratory, p. 17.

³R. D. Neirinckx, *Radiochem. Radioanal. Letters* 8, 59 (1971).

Cyclotron Products Pilot Production (L. O. Love)
(Production and Inventory Accounts)

January 1973 ORNL 86-Inch Cyclotron runs for ORNL and non-ORNL programs are given in Table 1.

Table 1. Cyclotron Irradiations and Runs for January 1973

Date	Customer	Product	Target	Time (hr:min)	Total Charges
<u>ORNL Programs</u>					
1-4-73	ORAU and others	Gallium-67	Zinc-68	9:15	\$ 886
1-18-73	ORAU and others	Gallium-67	Zinc-68	8:45	838
1-19-73	Isotopes Division	Bismuth-206	Lead	1:50	181
				19:50	\$ 1,905
<u>Non-ORNL Programs</u>					
12-22-72	New England Nuclear Corporation	Cobalt-57	Nickel-58	51:15	\$ 8,540
1-8-73	International Chemical & Nuclear Corp.	Gold-195	Platinum	6:15	1,447
1-11-73	International Chemical & Nuclear Corp.	Cobalt-57	Nickel-58	49:15	8,260
				106:45	\$18,247

In addition to routine maintenance, the oscillator tube was replaced, and a preset current meter was installed in the bias circuit to deenergize the high-voltage system during periods of excessive radio frequency. We are now using rebuilt oscillator tubes guaranteed to operate 1000 hr, and the cost is approximately 20% of a new tube. The tube removed was a rebuilt tube which had operated 1679 hr. Occasionally it was necessary to replace a radio-frequency cable in the bias system which was damaged by surges. This would interrupt operation of the cyclotron for periods up to 3 hr. Installation of the preset current meter in the bias circuit has reduced the occurrence of the radio-frequency cable failures.

Cyclotron operational cost for December was \$12,555.

FISSION PRODUCTS - 08-01-03

Krypton-85 Enrichment (R. A. Robinson)

The thermal diffusion unit with a cooling water leak into the gas annulus was removed from the cell. A pressure test confirmed the existence of a leak somewhere in the eight tubes of the light end section. The tube bundle was pulled out of the outer shell, and an inspection showed the tubes to be in good condition generally, but heavy deposits, apparently of dust in the cooling water, had accumulated around the outside of the tubes in spots on the downstream side of the internal cooling water baffles.

The individual tubes have not yet been removed for inspection, but it appears likely that the leak will be found to be due to overheating and burnout in the regions covered by the deposits.

Cesium-137 Pilot Production (R. W. Schaich)
(Production and Inventory Accounts)

1. Process Status

Eight batches of $^{137}\text{CsCl}$ totaling approximately 150,000 Ci were processed from "cesium carbonate" intermediate product prepared in November and December. At present the crystallizer inventory is approximately 110,000 Ci; this material is being purified for another oxalate cycle. The agitators in both the oxalate precipitators (in manipulator cells) are inoperable; so an attempt will be made to crystallize the oxalate in the cesium-137 purification crystallizers and then transfer the slurry to the manipulator cell equipment for filtration. Since there are so few oxalate batches (probably four) remaining to be run, it is not considered worthwhile to repair the agitators.

Water rinsing and long-term soaking (with 1.0 M HNO_3) of the cesium-137 storage tank did not result in the removal of any additional cesium-137. Preliminary decontamination of the cesium-137 storage and transfer system has begun. The remaining in-process cesium-137 consists of the crystallizer inventory (110,000 Ci), the cesium-137 glass residue (estimated at 35,000 Ci), and about 5,000 Ci of miscellaneous items such as returned analytical samples and reserved carbonate for special shipments. It is expected that routine cesium-137 process operations will be terminated in late February or early March. The current cesium-137 process status is as follows.

<u>Item</u>	<u>Cesium-137 (Ci)</u>
In-process material	150,000
$^{137}\text{CsCl}$ products	450,000
Sources in fabrication	^a
Completed sources awaiting shipment	202,250

^aA campaign for preparation of 40 "BNL strips" containing a total of approximately 180,000 Ci is in progress.

2. Operational Summary

<u>Item</u>	<u>Jan. 1973</u>		<u>CY 1973</u>		<u>FY 1973</u>	
	<u>No.</u>	<u>Ci</u>	<u>No.</u>	<u>Ci</u>	<u>No.</u>	<u>Ci</u>
HAPO shipments received	0	0	0	0	0	0
Product batches prepared	8	150,000	8	150,000	38	457,000
Sources						
Fabricated	8	22,750	8	22,750	34	48,450
Shipped	1	3,000	1	3,000	27	33,700
Special form cans						
Fabricated	0	0	0	0	10	500
Shipped	1	250	1	250	5	1,750

3. Current Orders

Current orders for cesium-137 as sources or bulk powder are listed below:

<u>Customer</u>	<u>Amount (Ci)</u>	<u>Estimated Shipping Date</u>
Brookhaven National Laboratory	~180,000	FY 1973
J. L. Shepherd and Associates	21,754	a
Radiochemical Centre	1,500	May 1973
General Radioisotope Products	200	March 1973

^aSources have been fabricated and are awaiting receipt of customer's container.

An order is on hand from Atomic Energy of Canada, Limited, for 63 kCi of cesium-137 as CsCl powder. The powder has been canned and stored, awaiting release by customer.

4. Source Fabrication

A 3,000-Ci source was shipped to J. L. Shepherd and Associates.

Strontium-90 Pilot Production (*R. W. Schaich*)
(Production and Inventory Accounts)

1. Process Status

No strontium-90 titanate processing was done this month. A special strontium-90 product batch for a customer was made by diluting strontium-90 feed. Since cesium-137 processing should be completed in the near future, plans are being made to begin strontium-90 processing in March. There are no present or expected orders for strontium-90 sources, so the strontium-90 (as the distrontium titanate) will be canned in doubly welded storage cans. The current strontium-90 process status is as follows:

<u>Item</u>	<u>Strontium-90 (Ci)</u>
In-process material	805,900
Strontium-90 products	426,200
Sources in fabrication	0
Returned SNAP sources	446,600
Completed sources awaiting shipment	221,000

2. Operational Summary

<u>Item</u>	<u>Jan. 1973</u>		<u>CY 1973</u>		<u>FY 1973</u>	
	<u>No.</u>	<u>Ci</u>	<u>No.</u>	<u>Ci</u>	<u>No.</u>	<u>Ci</u>
HAPO shipments received	0	0	0	0	0	0
Product batches prepared	0	0	0	0	0	0
Sources						
Fabricated	0	0	0	0	0	0
Shipped	0	0	0	0	0	0
Special form cans						
Fabricated	0	0	0	0	0	0
Shipped	0	0	0	0	1	10

3. Current Orders

Current orders for strontium-90 as sources or bulk powder are shown below:

<u>Customer</u>	<u>Amount (Ci)</u>	<u>Estimated Shipping Date</u>
U. S. Navy	221,000	FY 1973
Radiochemical Centre	500	May 1973

Short-Lived Fission Products Pilot Production (*R. W. Schaich*)
(Production and Inventory Accounts)

<u>Isotope</u>	<u>Number of Batches</u>	<u>Amount (Ci)</u>
Xenon-133	2	700
Iodine-131	2	55.5
Strontium-89	1	17.3
Barium-140	1	54.4

Promethium-147 Shipments and Current Orders

Donald W. Douglas Laboratories has placed an order for 200,000 Ci. Shipments of 50,000 Ci will be made in May, July, October, and December 1973.

SOURCE DEVELOPMENT — 08-01-04

Americium-241 (*F. N. Case*)

A ring source containing approximately 16 Ci americium-241 was returned by Vanderbilt University Medical Center for re-encapsulation into 16 cylindrical sources. An inactive prototype source was first prepared and tested under the ORNL standard source classification procedure to a III-C rating which is equal to the ring source and adequate for

Vanderbilt's requirements. The sources will be placed in an array around a collimator and used for secondary x-ray scanning of thyroid and brain.

Gadolinium-153 (*F. N. Case*)

Interest in the use of gadolinium-153 for medical diagnosis continues to increase. Another group at the University of California, Los Angeles, AEC Medical Center, has joined the program to evaluate gadolinium-153 in the form of sealed sources for various diagnostic procedures.

Two targets made from gadolinium-152 recovered from HFIR control plates were irradiated for the preparation of gadolinium-153. The product from this irradiation has been processed to solution, and a high-pressure ion-exchange column has been placed in operation for removal of terbium-160. Tracer runs using this column were made during the last week in January. Several in-process control devices utilizing gadolinium-153 have been developed by an AEC facility, and a paper describing their use is in preparation.

Prototype Source Testing (*R. A. Robinson*)

Two doubly encapsulated sources and one singly encapsulated cylindrical source were tested and found to meet the requirements for ORNL Class III-C. The first source was designed as a replacement for a previously tested⁴ $^{241}\text{AmO}_2$ ring-shaped source. It was designed to contain about 1 Ci of $^{241}\text{AmO}_2$ which was doubly encapsulated in stainless steel. Both inner and outer capsules had 0.020-in. walls and 0.008-in. windows. The second source was essentially the same design as a previously tested⁵ stainless steel californium-252 neutron source except that the encapsulation material was 0.050-in. Zircaloy instead of 0.050-in. stainless steel. The third source was the same as the second except that it was singly encapsulated rather than doubly encapsulated in 0.050-in. Zircaloy. The two Zircaloy sources were limited to Class III-C because they failed to pass the Class IV shear test and the Class D maximum temperature test. The americium-241 source was not tested for Class IV-D.

Radioisotope Characterization, Quality Control, and Standards (*S. A. Reynolds*)

1. Radioisotope Characterization

Values were selected for neutron cross sections for production of 90 common radionuclides. Adoptions by KAPL personnel for the new *Chart of*

⁴A. F. Rupp, *Radioisotope Program (8000) Progress Report for August 1971*, ORNL-TM-3558, Oak Ridge National Laboratory.

⁵A. F. Rupp, *Radioisotope Program (8000) Progress Report for March 1971*, ORNL-TM-3380, Oak Ridge National Laboratory.

the Nuclides were found to be in essentially complete agreement with our own selections. Product cross sections, i.e., for "burn-up" of the desired nuclides, were included where known. Representation from the U. S. Nuclear Data Committee was secured for the panel discussion during the special session being arranged by ANS-16 for the national ANS meeting in June.

2. Radioisotope Special Analysis and Quality Control

In connection with the assay of uranium-235 in special samples, specific activities were confirmed, methods and precisions were reviewed, and an additional measurement was recommended and interpreted. Gallium-67 preparations were obtained from the British Radiochemical Centre (RCC) and from a domestic supplier. Our measurements, using two independently calibrated instruments in each of two laboratories, were 0.8% below RCC and 1.6% above the domestic supplier. The RCC value was obtained by coincidence counting⁶ and was therefore little affected by assumptions about the decay scheme, but our measurements required utilization of data we selected from the literature which are quite different from those in the 1967 *Table of Isotopes*. In particular, a 30% error in assay would have resulted from use of the old percentage for the 0.300-MeV gamma radiation. Details of this study will be made available to domestic suppliers and users, NBS, and other standards groups and may contribute to resolution of discrepancies some have reported.

Our study of the measurement of xenon-133 has continued. The ionization chamber used for assay of whole shipments was recalibrated by use of mass-analyzed samples. The overall precision was about 6%, and the previous calibration was confirmed within 0 to 7%. According to data received from a commercial supplier, taking an NBS measurement as unity, ours would be 1.07, the supplier's 1.19, and a foreign source 1.73. It must be emphasized that the NBS measurement was made on a small sample, and the above comparison is tentative. Final resolution of the discrepancies awaits issuance of an NBS standard of appropriate level later this year.

It appears that the problem of tritium in heavy water has disappeared. A major commercial vendor reported that low-tritium material has been available all the time, when requested, and that all their supply is now low-tritium material. ASTM Committee D-19 declined to add tritium level to its specifications for heavy water, and members of ANS-16 advised against our attempting to set such a specification. Finally, there is no mention of tritium in the NRC specifications (*Specifications and Criteria for Biochemical Compounds*, 3rd., National Academy of Sciences, Washington, DC, 1972).

⁶V. E. Lewis *et al.*, *Int. J. Appl. Radiat. Isotopes* 23, 279 (1972).

RADIOISOTOPE SALES

(J. E. Ratledge)

Orders were received from U. S. Radium Corporation for 10,000 Ci of tritium gas, Industrial Nucleonics Corporation for 200 Ci krypton-85 (11.2% enriched), and Sumitomo Shoji America, Inc., for 100 Ci normal krypton-85. An order was received from Radiochemical Centre, England, for 150 Ci krypton-85 (50 Ci ~15% enriched and 100 Ci normal gas), 1500 Ci cesium-137 as calcined oxalate (30 cans of 50 Ci each), and 500 Ci strontium-90 as oxide (20 cans of 25 Ci each).

Shipments made during the month that may be of interest are listed below:

<u>Customer</u>	<u>Isotope</u>	<u>Quantity</u>
<u>Large Quantities</u>		
J. L. Shepherd and Associates	Cesium-137	3,000 Ci
Schwarz-Mann	Tritium	1,000 Ci
Canrad Precision Industries	Tritium	1,000 Ci
New England Nuclear Corporation	Tritium	5,000 Ci
Radiochemical Centre	Krypton-85, normal	100 Ci
American Atomics Corporation	Krypton-85, enriched	43.6 Ci
Radiochemical Centre	Krypton-85, enriched	50 Ci
Sumitomo Shoji America, Inc.	Krypton-85, normal	100 Ci
Measurex Corporation ^a	Krypton-85, enriched	973.8 Ci

<u>Withdrawn Items</u>		
University of Pittsburgh	Iodine-131, FP	50 mCi
Cleveland Metropolitan General Hospital	Iodine-131, FP	50 mCi
University of Rochester	Iodine-131, FP	450 mCi
University of Chicago	Copper-67	~13 mCi
Mayo Clinic	Copper-67	~13 mCi
University of California, Livermore	Cadmium-115m	0.9 Ci

<u>Items Used in Cooperative Programs</u>		
University of California, Livermore	Erbium-171-172	~4.65 Ci
Vanderbilt University	Bismuth-206	~5 mCi
Oak Ridge Associated Universities	Gallium-67	~300 mCi
University of Southern California	Platinum-195m	~35 mCi

<u>Unusual Items</u>		
U. S. Army Corps of Engineers	Sand tagged with gold-198-199	~40 Ci

^aBilling for material has been made; shipment is to be made at a later date.

A summary of the radioisotopes shipped during December 1972 is given in Table 2.

Table 2. Summary of Radioisotopes Shipped During December 1972

Isotope	Number of Shipments	Quantity (mCi)
Calcium-47	6	4
Cerium-144	1	2
Cesium-137	9	660,900
Cobalt-60	2	50
Copper-67	3	20
Europium-152-154	1	2
Gallium-67	11	443
Hafnium-181	1	8
Iodine-131, fission product	3	200
Krypton-85, normal	12	430,000
Krypton-85, enriched	2	302,950
Niobium-95	2	6
Phosphorus-33	3	202
Potassium-43	6	20
Promethium-147	5	51,040,050
Ruthenium-103	1	3
Strontium-90	6	10,250
Tritium	18	10,609,600
Xenon-133	53	75,020
Zirconium-95	1	1
Misc. compound preparations	15	150
Cyclotron irradiations		
New England Nuclear Corp.	Cobalt-57 as target	~2,000
N. V. Phillips-Duphar	Cobalt-57 as solution	400
Total		63,132,281

Radioisotope sales proceeds and shipments for the first six months of FY 1972 and FY 1973 are shown in Table 3.

Table 3. Radioisotope Sales and Shipments

Item	7-1-71 thru 12-31-71	7-1-72 thru 12-31-72
Inventory items	\$234,141	\$200,635
Major products	30,122	28,341
Radioisotope services	133,600	87,763
86-Inch Cyclotron irradiations	78,231	49,149
Miscellaneous processed materials	32,279	26,013
Packing and shipping	36,340	33,770
Total	\$544,713	\$425,671
Number of shipments	1,256	1,036

ADMINISTRATIVE

Travel of IDC personnel is given in Table 4.

Table 4. Travel by IDC Personnel

Traveler	Site Visited	Purpose of Visit
P. S. Baker	Washington, DC	Attend Highway Research Board Nuclear Principles and Applications Committee meeting
E. E. Beauchamp	Washington, DC	Attend ANSI N-14 Committee meeting on packaging and transportation of fissile and radioactive materials
J. K. Poggenburg	Chicago, IL	Attend Society of Nuclear Medicine Symposium on Cardiac Imaging in Nuclear Medicine
A. F. Rupp	Kansas City, MO	Give talk at ANS meeting.

PUBLICATIONS

REPORTS

A. F. Rupp, *Radioisotope Program (8000) Progress Report for December 1972*, ORNL-TM-4090, Oak Ridge National Laboratory.

**THIS PAGE
WAS INTENTIONALLY
LEFT BLANK**

INTERNAL DISTRIBUTION

1. M. A. Baker	23. H. H. Nichol
2. P. S. Baker	24. J. J. Pinajian
3. E. E. Beauchamp	25. M. E. Ramsey
4. G. E. Boyd	26. S. A. Reynolds
5-7. T. A. Butler	27-28. R. A. Robinson
8. F. N. Case	29. A. F. Rupp
9. W. R. Casto	30. R. W. Schaich
10. J. A. Cox	31. A. H. Snell
11. F. L. Culler	32. K. A. Spainhour
12. W. C. Davis	33. M. R. Skidmore
13. J. H. Gillette	34-35. H. F. Stringfield
14. H. R. Gwinn	36. J. R. Totter
15. R. F. Hibbs	37. D. B. Trauger
16. K. E. Jamison	38. A. M. Weinberg
17. Lynda Kern	39. J. C. White
18. E. H. Kobisk	40. A. Zucker
19. E. Lamb	41-42. Central Research Library
20. L. O. Love	43. Document Reference Section
21. W. S. Lyon	44-48. Laboratory Records Department
22. R. E. McHenry	49. Laboratory Records - RC

EXTERNAL DISTRIBUTION

50. G. A. Andrews, ORAU, Medical Division, Oak Ridge, Tennessee
51. H. L. Atkins, Brookhaven National Laboratory, Upton, New York
52. D. S. Ballantine, AEC, Washington, D. C.
- 53-56. R. F. Barker, AEC, Washington, D. C.
57. N. F. Barr, AEC, Washington, D. C.
58. G. L. Borsheim, ARHCO, Richland, Washington
59. C. R. Buchanan, AEC, Washington, D. C.
60. R. L. Butenhoff, AEC, Washington, D. C.
61. T. D. Chikalla, PNL, Richland, Washington
62. D. F. Cope, AEC Site Representative, ORNL
63. J. C. Dempsey, AEC, Washington, D. C.
64. B. J. Dropesky, LASL, Los Alamos, New Mexico
65. E. E. Fowler, AEC, Washington, D. C.
66. J. D. Goldstein, AEC, Washington, D. C.
67. A. Gottschalk, Argonne Cancer Research Hospital, Chicago, Illinois
68. F. D. Haines, AEC, Washington, D. C.
69. W. D. Holloman, AEC, Washington, D. C.
- 70-72. J. H. Jarrett, PNL, Richland, Washington
73. D. K. Jones, AEC, Richland, Washington
74. J. Lawrence, Lawrence Berkeley Laboratory, Berkeley, California
75. J. E. Machurek, AEC, Washington, D. C.
76. J. N. Maddox, AEC, Washington, D. C.
77. J. C. Malaro, AEC, Washington, D. C.
78. B. Manowitz, Brookhaven National Laboratory, Upton, New York
79. L. A. Miller, AEC, Washington, D. C.
80. W. E. Mott, AEC, Washington, D. C.

- 81. H. A. O'Brien, LASL, Los Alamos, New Mexico
- 82. G. J. Rotariu, AEC, Washington, D. C.
- 83. W. D. Sandberg, AEC, Aiken, South Carolina
- 84. R. W. Shivers, AEC, Washington, D. C.
- 85. F. J. Skozen (Krizek), Argonne Cancer Research Hospital, Chicago
- 86. Robert E. Smith, Atlantic Richfield Hanford Company, Richland, WA
- 87. L. G. Stang, Jr., BNL, New York
- 88-93. D. H. Turno, SRL, Aiken, South Carolina
- 94. A. R. Van Dyken, AEC, Washington, D. C.
- 95. Research and Technical Support Division, ORO
- 96-97. Technical Information Center